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Objectives The purpose of this study was to critically appraise guidelines on imaging of asymptomatic coronary artery
disease (CAD).
Background Various imaging tests exist to detect CAD in asymptomatic persons. Because randomized controlled trials are
lacking, guidelines that address the use of CAD imaging tests may disagree.
Methods Guidelines in English published between January 1, 2003, and February 26, 2010, were retrieved using MEDLINE, Cumula-
tive Index to Nursing and Allied Health Literature, the National Guideline Clearinghouse, the National Library for
Health, the Canadian Medication Association Infobase, and the Guidelines International Network International
Guideline Library. Guidelines developed by national and international medical societies from Western countries,
containing recommendations on imaging of asymptomatic CAD were included. Rigor of development was scored
by 2 independent reviewers using the Appraisal of Guidelines Research and Evaluation (AGREE) instrument. One
reviewer performed full extraction of recommendations, which was checked by a second reviewer.
Results Of 2,415 titles identified, 14 guidelines met our inclusion criteria. Eleven of 14 guidelines reported relationship
with industry. The AGREE scores varied across guidelines from 21% to 93%. Two guidelines considered cost ef-
fectiveness. Eight guidelines recommended against or found insufficient evidence for testing of asymptomatic
CAD. The other 6 guidelines recommended imaging patients at intermediate or high CAD risk based on the Fra-
mingham risk score, and 5 considered computed tomography calcium scoring useful for this purpose.
Conclusions Guidelines on risk assessment by imaging of asymptomatic CAD contain conflicting recommendations. More
research, including randomized controlled trials, evaluating the impact of imaging on clinical outcomes and
costs is needed. (J Am Coll Cardiol 2011;57:1591–600) © 2011 by the American College of Cardiology
Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.10.055As many as 50% of myocardial infarctions occur in persons
without a known history of symptomatic coronary artery
disease (CAD) (1). To diminish disease burden, primary
prevention on the individual level is currently rendered by
targeting high-risk subjects, who are identified by office-
based risk assessment using multiple traditional cardiovas-
cular risk predictors: age, sex, smoking, lipid levels, and
blood pressure. Screening using these traditional predictors,
however, misses a considerable proportion of persons who
will suffer from coronary events (2). Because symptomatic
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2010, accepted October 1, 2010.CAD has a pre-clinical detectable phase (i.e., coronary
atherosclerosis), early detection of CAD in apparently
healthy persons may be an important substitute for or
supplement to risk assessment based on the traditional risk
factors.
See page 1601
Because technical developments have created various
imaging techniques to assess a patient’s coronary condition,
clinicians are faced with multiple options to choose from.
Before a doctor decides to test for asymptomatic disease, the
intervention should meet a set of specific screening criteria
(3–5). Hence, clinicians and decision makers usually rely on
clinical practice guidelines in which recommendations are
made on the basis of these criteria. As opposed to cancer
screening, few large randomized controlled trials (RCTs)
studying the effect of early detection of CAD on event rates
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tion have been performed. In
absence of RCTs demonstrating
a net health benefit of imaging,
the weighing of harms and ben-
efits is more likely to result in
different judgments, and there-
fore, conflicting recommenda-
tions. Therefore, a critical ap-
praisal of guidelines and review
of the agreements and the differ-
ences among recommendations
can serve as a guide for deciding
which imaging tests to use in clini-
cal practice.
For this purpose, we systemat-
ically reviewed guidelines con-
taining recommendations on im-
aging of asymptomatic CAD
within the general population.
Methods
Data sources and searches. To
identify appropriate guidelines,
the literature search used for a
previous article on cardiovascular
risk assessment (6) was updated
and covered a period from Janu-
ary 1, 2003, to February 26,
2010. Briefly, MEDLINE, Cu-
mulative Index to Nursing and
Allied Health Literature (CI-
NAHL), and 4 guideline data-
bases—the National Guideline Clearinghouse (United
States), the National Library for Health (United Kingdom) on
Guideline Finder, Canadian Medical Association Infobase
(Canada), and the Guidelines International Network (G-I-N)
International Guideline Library—were searched. Searches
were limited to guidelines from the United States, Canada,
United Kingdom, Australia, and New Zealand, and inter-
national guidelines in the English language. A search on
websites of guideline development organizations was per-
formed for additional guidelines.
Study selection. Articles were considered if they met the
Institute of Medicine definition for clinical practice guide-
lines. The Institute of Medicine defines clinical practice
guidelines as “systematically developed statements to assist
practitioner and patient decisions about appropriate health
care for specific clinical circumstances.” If doubt existed
whether a report met this definition or not, we verified
eligibility by checking the inclusion of similar reports in the
National Guideline Clearinghouse. This database also uses
the Institute of Medicine definition. For this reason, we also
considered American Heart Association (AHA) expert
Abbreviations
and Acronyms
ACCF  American College
of Cardiology Foundation
AGREE  Appraisal of
Guidelines Research and
Evaluation
AHA  American Heart
Association
CAD  coronary artery
disease
CAR  Canadian
Association of Radiologists
CCS  Canadian
Cardiovascular Society
CT  computed
tomography
ECG  electrocardiography
MR  magnetic resonance
NCEP  National
Cholesterol Education
Program
NZGG  New Zealand
Guidelines Group
PET  positron emission
tomography
RCT  randomized
controlled trial
SPECT  single-photon
emission computed
tomography
USPSTF  U.S. Preventive
Services Task Forceconsensus documents and scientific statements, and Amer-ican College of Cardiology Foundation (ACCF) appropri-
ateness criteria reports. We included guidelines if they: 1)
contained recommendations on imaging of asymptomatic
CAD specifically aimed to prevent a first coronary event; 2)
involved apparently healthy persons, that is adults without,
for example, diabetes mellitus; and 3) were produced on
behalf of a national or international medical specialty
society. For completeness, we also included guidelines on
electrocardiography and exercise tolerance tests, because
these tests are traditionally used in the diagnosis of CAD.
The SRS 4.0 (Mobius Analytics, Ottowa, Ontario,
Canada), a web-based software package developed for
systematic review data management, was used. Review of
titles and abstracts was performed independently by 2
reviewers (B.S.F. and E.B.C.). For a paper to be ex-
cluded, both reviewers had to agree that the article was
ineligible. For abstracts, disagreements between the re-
viewers were discussed and resolved by consensus. The
final selection based on the full text was performed by the
first author.
Data extraction and quality assessment. One reviewer
(B.S.F.) extracted all relevant recommendations from each
included guideline. A second reviewer (T.S.S.G.) checked
the results obtained for accuracy and completeness. Discrep-
ancies were resolved by consensus. Each guideline could
provide 1 or more relevant recommendations. Data ex-
tracted on a guideline level included the reported method-
ology for evidence synthesis, and formulating of recommen-
dations. On the recommendation level, we extracted data on
consideration of cost effectiveness, the target population, the
strategy for delivery of the test, coronary atherosclerosis
tests, intervention, and follow-up. In addition, the strength
of the recommendation was classified as “for,” “consider,”
“not for, not against,” “insufficient evidence,” or “against.”
We assessed the quality of development for each included
guideline using the 7-item Rigor of Development domain of
the Appraisal of Guidelines Research and Evaluation
(AGREE) instrument (7). This domain considers the re-
porting of: 1) methods to search for evidence; 2) criteria for
selecting the evidence; 3) methods for formulating the
recommendations; 4) consideration of health benefits, side
effects, and risks; 5) supporting evidence; 6) procedures for
external peer review; and 7) the update process. Each item
was independently rated on a 4-point Likert scale by 2
reviewers (B.S.F. and T.S.S.G.). Websites of guideline
developers were examined by both reviewers for additional
information on the development processes. For each re-
viewer, AGREE scores were calculated as a percentage
using the sum of the 7 items and the maximum possible
score. If the total AGREE scores of the 2 reviewers differed
20%, a third independent reviewer (J.J.V.) also assessed
the guideline. Final rigor scores were calculated by averaging
the AGREE scores from all reviewers. Three guidelines
(8–10) were rated by 3 reviewers. We ranked included
guidelines according to their score. Editorial independence
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line panel member-industry relationships, and disclosure of
identities and relationships with industry of peer reviewers
were assessed by 1 reviewer (B.S.F.) and checked by a
second reviewer (T.S.S.G.). Discrepancies were resolved by
consensus.
Data synthesis and analysis. A table for comparison of the
recommendations from the selected guidelines was con-
structed. The table was divided into 1) methodology of
guideline development; 2) consideration of cost effectiveness
regarding the recommendation; 3) target group and delivery
of early detection; 4) tests considered; and 5) thresholds for
intervention and follow-up. Agreement between reviewers
on AGREE scores was assessed using the intraclass corre-
lation coefficient. Given the limited number of guidelines,
only explorative quantitative analyses were possible. We
examined the correlation between the proportion of guide-
line panel members who reported relationships with indus-
try and the AGREE score with guidelines as units of
analysis. Furthermore, we examined whether the proportion
of panel members with industry relationships and the
AGREE score were associated with a positive recommen-
dation (“consider” or “for”) by logistic regression. Two
guidelines that had no explicit statement on conflicts of
interest of panel members were excluded from the analyses.
An alpha level of 0.05 was used to indicate statistical
significance. All analyses were performed using SPSS,
version 15.0 (SPSS Inc., Chicago, Illinois).
Results
Selected guidelines. Fourteen guidelines (11–22) relevant
to testing of asymptomatic CAD were eligible for full data
extraction (Fig. 1). Table 1 summarizes the selected guide-
lines, together with AGREE score and conflict of interest
results. Most guidelines (10 of 14) were developed in the
United States. The AGREE scores varied from 21% to
93%, with a median AGREE score of 57%. Reproducibility
of the 2 reviewers’ average AGREE scores was good, with
an intraclass correlation coefficient of 0.76. Examples of low
scoring guidelines are the ACCF appropriateness criteria
reports (ACCF2-4) (20–22). These guidelines provided
excellent information on the methods followed for achieving
consensus and formulating recommendations, but did not
contain detailed information on the search strategy used to
identify the evidence. Although “a standardized literature
review” was performed for these reports, key words used in
the search strategy, and inclusion and exclusion criteria for
selecting articles were not reported. In addition, these
guidelines did not explicitly discuss benefits and harms of
recommendations and methodology for guideline updating.
Twelve of the 14 guidelines contained disclosure of
relationships with industry, and in 11, at least 1 panel
member declared having a relevant financial relationship. In
this limited set of 12 guidelines, no relationship between the
AGREE score and the proportion of panel members withan industry relationship was observed (Pearson’s correlation
r  0.205; p  0.523).
General findings among the recommendations. The 14
included guidelines contained 26 recommendations on test-
ing of asymptomatic CAD (Table 2). The following tests
were considered: computed tomography (CT) calcium scor-
ing, CT angiography, magnetic resonance (MR) angiogra-
phy, single-photon emission computed tomography
(SPECT), positron emission tomography (PET), stress
echography, resting electrocardiography, and exercise toler-
ance testing. The majority of guidelines, except for the
Canadian Cardiovascular Society (CCS) 2 guideline (19),
Figure 1 Literature Search and Selection
Numbers of guidelines for each step of the process are indicated. Group totals
may exceed the reported numbers for the excluded articles at abstract and full
text level because several reasons for exclusion were allowed. CAD  coronary
artery disease; CINAHL  Cumulative Index to Nursing and Allied Health Litera-
ture; CMA  Canadian Medical Association; G-I-N  Guidelines International
Network; NGC  National Guideline Clearinghouse.were based on a comprehensive review including study
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Radiologists (CAR) (18) and CCS2 (19) guidelines, a
grading system for assigning the level of evidence was used.
Evaluation of cost effectiveness of recommended tests was
explicitly done in only 2 guidelines, the U.S. Preventive
Services Task Force (USPSTF) 1 (11) and ACCF1 (15)
guidelines, by reviewing decision modeling studies on exer-
cise tolerance testing (23–25) and CT calcium scoring
(26,27), respectively. However, both guideline groups were
unable to find a sufficient number of high-quality cost-
effectiveness analyses on which to base their recommenda-
tions. In other guidelines (ACCF2 [20] and ACCF4 [22]),
group members were requested to consider costs in their
decision making as well, but this was not based on a review
of cost-effectiveness studies or decision analyses.
Eight of the 14 guidelines recommended against or con-
cluded that there is insufficient evidence for testing of asymp-
tomatic CAD. In the remaining 6 guidelines (ACCF1 [15],
AHA2 [8], National Cholesterol Education Program [NCEP]
[16,17], CAR [18], CCS2 [19], and ACCF2 [20]), testing
was only advocated for patients with an a priori elevated risk
level based on absolute CAD risk or multiple risk factors.
Generally, risk was determined by Framingham risk equations
for estimation of a 10-year risk for coronary events (fatal and
nonfatal) using the categories 10%, 10% to 20%, and 20%
or, respectively, low, intermediate, and high risk. However, 2
uidelines (CAR [18] and CCS2 [19]) did not specify any
riteria for low, intermediate, and high risk. None advocated a
niversal screening approach or screening based on an age
riterion alone. Whether a guideline contained a recommen-
Characteristics of 14 Guidelines on Imaging of Asymptomatic CoroTable 1 Characteristics of 14 Guidelines on Imaging of Asympt
Guideline Identifier,
Year (Ref. #)
Organization(s) Responsible for
Guideline Development Coun
USPSTF1, 2004 (11) U.S. Preventive Services Task Force Uni
USPSTF2, 2009 (12) U.S. Preventive Services Task Force Uni
NZGG, 2003 (13) New Zealand Guidelines Group New
AHA1, 2008 (14) American Heart Association Uni
ACCF1, 2007 (15) American College of Cardiology Foundation,
American Heart Association
Uni
CCS1, 2009 (10) Canadian Cardiovascular Society Can
AHA2, 2006 (8) American Heart Association Uni
AHA3, 2005 (9) American Heart Association Uni
NCEP, 2002, 2004
update (16,17)
National Heart, Lung, and Blood Institute,
American College of Cardiology Foundation,
and American Heart Association
Uni
CAR, 2009 (18) Canadian Association of Radiologists Can
CCS2, 2009 (19) Canadian Cardiovascular Society Can
ACCF2, 2009 (20) American College of Cardiology Foundation, et al. Uni
ACCF3, 2008 (21) American College of Cardiology Foundation, et al. Uni
ACCF4, 2006 (22) American College of Cardiology Foundation, et al. Uni
*Relationship with industry reported by at least 1 person.
ACCF  American College of Cardiology Foundation; AHA  American Heart Association; CAR 
identities of peer reviewers; DIRp disclosure of the identities of peer reviewers for some parts of t
public organization reported; NCEP  National Cholesterol Education Program; NZGG  New Zea
statement about conflicts of interest of external peer reviewers present.ation that supports testing or not did not statistically signif- tcantly depend on AGREE score or proportion of panel
embers with industry relationships. Adjusted odds ratios per
0% increase were 0.73 (95% confidence interval: 0.41 to 1.33)
nd 0.68 (95% confidence interval: 0.35 to 1.32), respectively.
The indications for further testing and primary preventive
easures were not described in much detail. Overall, in
uidelines that recommended for consideration of testing of
symptomatic CAD within an intermediate-risk population
ACCF1 [15], AHA2 [8], NCEP [16,17], CAR [18], and
CS2 [19]), all (previous intermediate risk) subjects were
arked as high risk after a positive test. None of these
uidelines contained recommendations in which traditional
rediction models were updated by including test results as
ovariate. In addition, none of the guidelines reported
hether the tests should be performed once or periodically
n case of a negative test result.
T calcium scoring. Most guidelines (10 of 14) considered
he CT calcium score as a test for improvement of total
oronary risk assessment based on traditional risk factors.
mong these 10 guidelines (USPSTF1 [11], USPSTF2 [12],
ew Zealand Guidelines Group [NZGG] [13], ACCF1 [15],
CS1 [10], AHA2 [8], NCEP [16,17], CAR [18], CCS2
19], and ACCF4 [22]), 4 guidelines (ACCF1 [15], AHA2
8], NCEP [16,17], and CCS2 [19]) concluded that there was
ufficient evidence for consideration of its use, and 1 guideline
CAR) (18) recommended for its use. These guidelines rec-
mmended CT calcium scoring solely in an intermediate
AD risk population. In contrast, the USPSTF2 (12),
ZGG (13), and ACCF4 (22) guidelines concluded that
here is insufficient evidence for the intermediate-risk popula-
Artery Diseaseic Coronary Artery Disease
plied
AGREE
Rigor Score, % Conflicts of Interest
Proportion of Panel Members
With Reported Industry
Relationships
tes 93 EI, DIRp —
tes 90 EI, SCI 0/23
and 79 EI, FPO, SCI,* DIRp 9/35
tes 76 SCI,* DIR, SCIR 8/11
tes 74 SCI,* DIR, SCIR* 4/14
59 SCI* 20/23
tes 57 SCI,* DIR, SCIR* 1/4
tes 57 SCI,* DIR, SCIR* 6/12
tes 52 SCI,* DIR 6/28
36 — —
31 SCI* 1/13
tes 24 SCI,* DIRp, SCIR* 13/29
tes 21 SCI,* DIRp, SCIR* 15/23
tes 21 SCI,* DIRp, SCIR* 11/25
ian Association of Radiologists; CCS  Canadian Cardiovascular Society; DIR  disclosure of the
elines; EI editorial independence from funding organization declared; FPO funding by external
uidelines Group; SCI  statement about conflicts of interest of panel members present; SCIR naryomat
try Ap
ted Sta
ted Sta
Zeal
ted Sta
ted Sta
ada
ted Sta
ted Sta
ted Sta
ada
ada
ted Sta
ted Sta
ted Sta
Canad
he guidion. For low CAD risk persons and persons already known to
Recommendations (n  26) in Guidelines (n  14) on Imaging of Asymptomatic CADTable 2 Recommendations (n  26) in Guidelines (n  14) on Imaging of Asymptomatic CAD
USPSTF1 USPSTF1 USPSTF2 NZGG AHA1
AGREE rigor score, % 93% 93% 90% 79% 76%
Method to evaluate evidence Systematic review* covering
1966–June 2002
Systematic review* covering
1966–June 2002
Systematic review* covering
1966–July 2008; meta-analysis
Systematic review* covering
1989–August 10, 2002;
review of published
systematic reviews, meta-
analyses or guidelines
Standardized review†
with MEDLINE search
covering 1990–2006
Method to formulate
recommendations
Expert consensus Expert consensus Expert consensus Expert consensus Expert consensus
Consideration of costs Yes, a review of cost-effectiveness
studies is performed
Yes, a review of cost-effectiveness
studies is performed
No, because of limitations in evidence
of effectiveness, little information
available on cost-effectiveness
NR NR
Target group Adults at low CAD risk: 5%–10%
10-yr risk of CAD events
Adults at increased CAD risk:
15%–20% 10-yr risk of
CAD events
Adults at intermediate CAD risk: 10-yr
CAD risk 10%–20% (FRS)
Adults regardless of risk Adults regardless of risk
Strategy Opportunistic screening/case-finding Opportunistic screening/case-finding Opportunistic screening/case-finding NR NR
Strength of recommendation Against Insufficient evidence to make a
recommendation
Insufficient evidence to make a
recommendation
Insufficient evidence to make a
recommendation
Against
Tests considered CTCS; r-ECG; ETT CTCS; r-ECG; ETT CTCS CTCS CTA; MRA
Intervention(s) considered More intensive risk factor modification
or follow-up testing/ICA if: presence
of calcium, r-ECG abnormalities,
ST-segment depression 1 mm;
CABG/PCI if severe CAS
More intensive risk factor modification
or follow-up testing/ICA if: presence
of calcium, r-ECG abnormalities,
ST-segment depression 1 mm;
CABG/PCI if severe CAS
Aggressive risk reduction if reclassified
10-yr CAD risk 20% using CAC
score categories: none, 1–100,
101–300, and 300,
no established norms for general
population
Statins, aspirin, and intensive
lifestyle therapy if 5-yr CVD
risk 15%, cut-off values for
CAC score not specified
NR
Screening intervals NR NR NR Traditional risk assessment:
annually if 5-yr CVD risk
15%, in 5 yrs if 5-year CVD
risk 5%–15%, in 10 years if
5-yr CVD risk
5%; NR for CTCS
NR
ACCF1 ACCF1 CCS1 AHA2 AHA2
AGREE rigor score, % 74% 74% 59% 57% 57%
Method to evaluate evidence Standardized review† with MEDLINE
search covering 1998–early 2005;
review of published systematic
reviews, meta-analyses, or guidelines
Standardized review† with MEDLINE
search covering 1998–early 2005;
review of published systematic
reviews, meta-analyses, or guidelines
Systematic review* covering
January 1, 2006–February 1,
2009; review of published
systematic reviews, meta-
analyses, or guidelines
Standardized review† Standardized review†
Method to formulate
recommendations
Expert consensus Expert consensus Expert consensus Expert consensus Expert consensus
Consideration of costs Yes, review of cost-effectiveness studies
performed
Yes, review of cost-effectiveness studies
performed
NR NR NR
Continued on next page
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ACCF1 ACCF1 CCS1 AHA2 AHA2
Target group Adults at high CAD risk: 10-yr risk of
CAD events 20% or other high-risk
diagnosis; adults at low CAD risk:
10-yr risk of CAD events 10%
Adults at intermediate CAD risk:
10-yr risk of CAD events 10%–20%
Men 40 yrs of age, women
50 yrs of age or post-
menopausal, adults at any
age and 1 cardiovascular
risk factor (family history of
premature CAD, smoking,
obesity)
Clinically selected intermediate
CAD risk patients (e.g., those
with a 10-yr CAD risk 10%–
20% FRS)
Adults regardless of risk
Strategy NR NR NR NR NR
Strength of recommendation Against Consider Insufficient evidence to make a
recommendation
Consider Against
Tests considered CTCS CTCS CTCS; ETT CTCS h-SPECT-CT/h-PET-CT
Intervention(s) considered Pharmacologic treatment according to
NCEP guidelines if 10-yr CAD risk
20% based on high CAC score
(400)
Pharmacologic treatment according to
NCEP guidelines if 10-yr CAD risk
20% based on high CAC score
(400)
Statins and lifestyle intervention
if subclinical atherosclerosis
More aggressive target values
for lipid-lowering therapies if
high CAC score based on
absolute plaque burden
NR
Screening intervals NR NR NR Serial imaging for assessment
of progression of coronary
calcification is not indicated
at this time
NR
AHA3 NCEP CAR CAR CAR
AGREE rigor score, % 56% 52% 36% 36% 36%
Method to evaluate evidence Standardized review†; review of
published guideline
Standardized review† of literature
identified by the panel members and
by a MEDLINE search; review of
published systematic reviews, meta-
analyses, or guidelines;
Systematic review* covering
1966–October 2008; review
of published systematic
reviews, meta-analyses, or
guidelines
Systematic review* covering
1966–October 2008; review
of published systematic
reviews, meta-analyses, or
guidelines
Systematic review*
covering 1966–October
2008; review of
published systematic
reviews, meta-analyses,
or guidelines
Method to formulate
recommendations
Expert consensus Expert consensus Expert consensus Expert consensus Expert consensus
Consideration of costs NR NR for this recommendation NR NR NR
Target group Adults regardless of risk 2002: multiple risk factors and 10-yr
CAD risk 20% (FRS), 0–1 risk factor
and LDL-C 160–189 mg/dl after
lifestyle changes; 2004 update: 10-yr
CAD risk 10%–20% (FRS) and LDL-C
100–129 mg/dl
Adults at intermediate CAD risk Adults at low CAD risk or
high CAD risk
Adults regardless of risk
Strategy NR Opportunistic screening/ case-finding NR NR NR
Strength of recommendation Insufficient evidence to make a
recommendation
Consider For Against Against
Screening tests considered ETT 2002: CTCS; ETT; SPECT/PET;
2004 update: CTCS
CTCS CTCS CTA
Intervention(s) considered NR 2002: Statins and lifestyle intervention if
subclinical atherosclerosis; 2004
update: consider statins if CAC score
75th percentile for person’s age and
sex to achieve LDL-C100 mg/dl
Calcium scoring using a
traditional scoring system
may influence decision to
intensify risk factor
modification
Calcium scoring using a
traditional scoring system
may influence decision to
intensify risk factor
modification
If CAS 50%,
intervention(s) not
further specified
Screening intervals NR Traditional risk assessment in 3 months
–1 year depending on LDL-C level, NR
for recommended tests
NR NR NR
Continued on next page
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ContinuedTable 2 Continued
CCS2 CCS2 ACCF2 ACCF2 ACCF2
AGREE rigor score, % 31% 31% 24% 24% 24%
Method to evaluate evidence Review‡ Review‡ Standardized review† Standardized review† Standardized review†
Method to formulate
recommendations
Expert consensus Expert consensus Expert consensus: Delphi
method
Expert consensus: Delphi
method
Expert consensus: Delphi
method
Consideration of costs NR NR Cost considered implicitly in the
appropriateness
determination
Cost considered implicitly in the
appropriateness
determination
Cost considered implicitly
in the appropriateness
determination
Target group Adults at intermediate CAD risk Adults regardless of risk Adults at low CAD risk or at
intermediate CAD risk (FRS)
with interpretable ECG
Adults at intermediate CAD risk
(FRS) with uninterpretable ECG
Adults at high CAD risk
(FRS)
Strategy NR NR NR NR NR
Strength of recommendation Consider Against Against Insufficient evidence to make a
recommendation
Consider
Screening tests considered CTCS CTA SPECT SPECT SPECT
Intervention(s) considered NR Optimal medical therapy; PCI; CABG if test
results consistent with high-risk CAD
NR NR NR
Screening intervals NR NR NR NR NR
ACCF3 ACCF3 ACCF4 ACCF4 ACCF4 ACCF4
AGREE rigor score, % 21% 21% 21% 21% 21% 21%
Method to evaluate evidence Standardized review† Standardized review† Standardized review† Standardized review† Standardized review† Standardized review†
Method to formulate
recommendations
Expert consensus: Delphi method Expert consensus: Delphi method Expert consensus: Delphi
method
Expert consensus: Delphi
method
Expert consensus: Delphi
method
Expert consensus: Delphi
method
Consideration of costs NR NR Cost considered implicitly
in the appropriateness
determination
Cost considered implicitly
in the appropriateness
determination
Cost considered implicitly
in the appropriateness
determination
Cost considered implicitly
in the appropriateness
determination
Target group Adults at low CAD risk or
intermediate CAD risk (FRS)
Adults at high CAD risk (FRS) Adults at low CAD risk or
intermediate CAD risk
(FRS)
Adults at high CAD risk
(FRS)
Adults at low CAD risk
(FRS)
Adults at intermediate CAD
risk or high CAD risk
(FRS)
Strategy NR NR NR NR NR NR
Strength of recommendation Against Insufficient evidence to make
recommendation
Against Insufficient evidence to
make recommendation
Against Insufficient evidence to
make recommendation
Screening tests considered SE SE CTA CTA CTCS CTCS
Intervention(s) considered NR NR NR NR NR NR
Screening intervals NR NR NR NR NR NR
*Comprehensive literature review, which includes a search strategy that covers multiple databases and other sources, study selection criteria, and quality assessment of the evidence. †Comprehensive literature review, which includes quality assessment of the evidence.
‡Comprehensive literature review without systematic methods.
CABG  coronary artery bypass graft; CAD  coronary artery disease; CAS  coronary artery stenosis; CT  computed tomography; CTA  computed tomography angiography; CTCS  computed tomography calcium score; CVD  cardiovascular disease; ETT  exercise
tolerance test; FRS  Framingham Risk Score; h-SPECT  hybrid single-photon emission computed tomography; h-PET  hybrid positron emission tomography; ICA  invasive coronary angiography; LDL-C  low-density lipoprotein cholesterol; MRA magnetic resonance
angiography; NR  not reported; PCI  percutaneous coronary intervention; PET  positron emission tomography; r-ECG  resting electrocardiography; SE  stress echocardiography; SPECT  single-photon emission computed tomography.
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Guidelines on Imaging of Asymptomatic CAD April 12, 2011:1591–600be at high CAD risk, guidelines were unanimous in not
advocating CT calcium scoring.
Electrocardiography and exercise tolerance testing. The
USPSTF1 guideline (11) recommended against performing
electrocardiography testing in a low-risk population and found
insufficient evidence for subjects at elevated risk. No other
guidelines provided recommendations for this test. Exercise
tolerance testing was considered in 4 guidelines (USPSTF1
[11], NCEP [16,17], CCS1 [10], and AHA3 [9]): 1 (NCEP
16,17]) recommended considering testing, and 3 (CCS1 [10],
SPSTF1 [11], and AHA3 [9]) were inconclusive.
yocardial perfusion imaging. Single-photon emission
omputed tomography was considered in 3 guidelines
AHA2 [8], NCEP [16,17], and ACCF2 [20]), of which 2
AHA2 [8] and NCEP [16,17]) also considered PET. The
HA2 guideline (8) recommended against any use of
yocardial perfusion imaging in asymptomatic subjects,
hereas the NCEP (16,17) and ACCF2 (20) guidelines
ecommended its use for different target populations: either
or intermediate-risk subjects (NCEP [16,17]) or solely for
hose at high risk (ACCF2 [20]).
T angiography and MR angiography. The AHA1 (14),
AR (18), CCS2 (19), and ACCF4 (22) guidelines con-
idered these tests for the asymptomatic population. None
f these guidelines advocated their use. For subjects at high
isk, insufficient evidence was found by the ACCF4 guide-
ine (22).
tress echocardiography. Only 1 guideline (ACCF3 [21])
rovided recommendations for stress echocardiography. For
dults at high risk, insufficient evidence was found for its
se; for the remaining asymptomatic population, stress
chocardiography is not justified according to the ACCF3
uidelines (21).
iscussion
n summary, we identified 14 guidelines on testing of asymp-
omatic CAD. In the development of most guidelines, rela-
ionships with the industry were present. A considerable
umber of guidelines achieved a low AGREE score. Various
nconsistencies were observed among the guidelines regarding
nterpretation of the value of early detection of CAD. Many
uideline groups recommended against testing of asymptom-
tic CAD or concluded that there is insufficient evidence. The
uidelines that contained recommendations to consider testing
f asymptomatic CAD only reported benefit for those at
levated risk, that is, those who were either at intermediate or
igh absolute risk for having a CAD event. The majority of
hese guidelines supported consideration of CT calcium scor-
ng in case of intermediate CAD risk.
Some possible limitations of this review deserve attention.
irst, only guidelines developed by national or international
edical specialty organizations were reviewed. Hence, guide-
ines developed by local organizations, private organizations,
nd individual experts were not considered. An example of an
ften-cited guideline, therefore, not included is the Society for neart Attack Prevention and Eradication (SHAPE) guideline
28). The SHAPE guideline recommends periodic measure-
ent of coronary calcium or carotid intima-media thickness in
ll asymptomatic men ages 45 to 75 years and women ages 55
o 75 years except those defined at very low risk. Such a
niversal screening approach is, however, not advocated by any
f the guidelines included in this systematic review. Second, we
sed the AGREE instrument, which provides an overall score
f the construction process of guidelines, not components.
lthough we expect that the quality of development across the
hole guideline influences the quality of individual recommen-
ations, in theory, a solid recommendation could be created
ithin a poorly developed guideline and vice versa. Third, the
GREE instrument only considers the reported information
elated to the development of the guideline. The actual quality
f the guideline development can, therefore, not be fully
aptured. For example, guideline groups that performed a full
earch for evidence and that did not report detailed informa-
ion on the search strategy followed, received a low AGREE
core for this item. In reality, the search followed may be
dequate for identifying solid evidence. Fourth, it was difficult
o quantify the true degree of influence by industry relation-
hips, also because guidelines did not report payment amounts.
ifth, the ability to detect statistically significant relationships
n the quantitative analyses, such as an association between
ndustry relationships and the likelihood of a positive recom-
endation, was limited owing to the small set of included
uidelines.
The disagreements on the value of early detection of CAD
cross the guidelines could partly be explained by the paucity of
xperimental research. A search on ClinicalTrials.gov (29) up
o March 22, 2010, using search terms “coronary artery
isease” and “prevention” or “screening,” provided 97 interven-
ional studies. We found 5 RCTs on the effect of early
etection of CAD versus current practice of risk assessment
sing traditional risk factors. Only 1 RCT (ClinicalTrials.gov
dentifier: NCT00927693) was conducted in an apparently
ealthy population, with CT calcium scoring as the interven-
ion. The study’s results on hard endpoints are, however, not
et published (30). One RCT (ClinicalTrials.gov identifier:
CT00769275) was performed in a population with diabe-
es and revealed no effect of screening by myocardial
erfusion scans on cardiac event rates, although event rates
n the screened and not-screened groups were low, and no
tandardized preventive treatment strategy was used (31).
ther RCTs (ClinicalTrials.gov identifiers: NCT00431977,
CT00488033, and NCT00547872), on CT angiography
nd exercise tolerance testing, were also conducted in diabetic
atients, and are still ongoing.
Patients with subclinical atherosclerosis identified by
ccurate imaging tests can be expected to benefit from
reventive treatment because they are at elevated risk for an
vent. Ideally, decision making as to whether imaging
ndividual patients is beneficial should be based on RCTs
omparing preventive measures guided by imaging versus
ot imaging and evaluating CAD event rates as outcome.
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April 12, 2011:1591–600 Guidelines on Imaging of Asymptomatic CADSuch RCTs are, however, expensive and time-consuming
and not always feasible. In the absence of these RCTs, one
would want to combine data from trials evaluating the effect
of preventive measures with data from cohort studies re-
porting the association between imaging test results and
CAD event rates. Qualitatively weighing and combining
the relevant harms and benefits, as was done in the devel-
opment of the reviewed guidelines, is difficult and may lead
to different judgments about net health gains. Disagree-
ments across guidelines can occur for other reasons, includ-
ing different judgments about which research is relevant;
risk of biases in selected research; the applicability of the
research findings to the key questions; the relative impor-
tance of the anticipated costs; and also poor guideline
development processes and conflicts of interests (32). We
explored whether the latter 2 influenced the variation in
recommendations, but found no evidence for this in the
limited set of guidelines reviewed. Quantitatively, as op-
posed to qualitatively, weighing harms and benefits can be
done using decision models that integrate the best-available
evidence from multiple sources. Beneficial effects, adverse
effects, and incurred costs of preventive treatment and
follow-up can be summarized in an incremental cost-
effectiveness ratio. In a few of the included guidelines,
decision modeling studies were discussed; however, their
quality was considered too low for policy making.
The recommended methods of refining CAD risk strat-
ification using imaging test results can be improved by
updating existing prediction models (33). None of the
guidelines contained recommendations for the use of pre-
diction models combining traditional risk factors and test
results to calculate a new risk estimate. Instead, the
Framingham-based intermediate risk (10% to 20% 10-year
CAD risk) is reclassified to high risk (a 10-year CAD risk
20%), if the test result is positive, rather than updating the
risk estimate. This approach has limitations. First, it re-
quires consensus on these risk categories, which is not the
case. Second, validity of the reclassified risk might become
an issue. A positive test result may not elevate the predicted
absolute CAD risk to the level of high risk if the subject was
at the lower end of the intermediate risk distribution, for
example, if the 10-year CAD risk was between 10% and
15% (34). Reported risk ratios of asymptomatic CAD
adjusted for traditional risk factors, which might reclassify
individuals, are usually derived from a comparison with a
reference group without or with low indication for asymp-
tomatic CAD (34–37). However, converting a risk ratio to
absolute risk also depends on the distribution of the risk
marker within the general population, which consists of
subjects with and without this risk marker (38). Finally, a
communication of a refined numerical risk theoretically
offers a benefit in informing patients. Thus, we believe that
future research should also focus on the value of updating
traditional prediction models.Conclusions
Guidelines on risk assessment by imaging of asymptomatic
CAD contain conflicting recommendations. More research,
including RCTs, evaluating the impact of imaging on
clinical outcomes and costs is needed.
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